Cover Image
市場調查報告書

胰外分泌功能不全:開發中產品分析

Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 293887
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
胰外分泌功能不全:開發中產品分析 Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 42 Pages
簡介

胰外分泌功能不全(EPI)是特徵為缺乏胰外分泌酵素的疾病,會引起消化不良。症狀有腹瀉,軟便,無法吸收脂肪的脂肪便,缺乏維他命,食慾不振,原因不明的體重減少等。治療有胰酵素補充療法(PERT),生活習慣的改善等。

本報告涵括全球胰外分泌功能不全治療藥的開發中產品,提供目前開發平台狀況和最新趨勢,後期階段及中止的計劃的資訊,主要企業及他們開發中的產品檢討等資訊。

簡介

  • 調查範圍

胰外分泌功能不全概要

治療藥的開發

  • 開發中產品概要
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

胰外分泌功能不全:開發治療藥的企業

  • Anthera Pharmaceuticals Inc
  • Celleron Therapeutics Ltd
  • Cilian AG
  • Laboratoires Mayoly Spindler SAS
  • Nordmark Arzneimittel GmbH & Co KG

藥物簡介

暫停中的計劃

中止的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9424IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017, provides an overview of the Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline landscape.

Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. Symptoms include diarrhea, loose, oily stools with unabsorbed fat (steatorrhea), vitamin deficiencies, loss of appetite, and unexplained weight loss. Treatment includes pancreatic enzyme replacement therapy (PERT) and lifestyle modifications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Exocrine Pancreatic Insufficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 1 respectively.

Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Exocrine Pancreatic Insufficiency - Overview
    • Exocrine Pancreatic Insufficiency - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Exocrine Pancreatic Insufficiency - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development
    • Anthera Pharmaceuticals Inc
    • Celleron Therapeutics Ltd
    • Cilian AG
    • Laboratoires Mayoly Spindler SAS
    • Nordmark Arzneimittel GmbH & Co KG
  • Exocrine Pancreatic Insufficiency - Drug Profiles
    • burlulipase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cilase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CXD-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • liprotamase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MS-1819 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Exocrine Pancreatic Insufficiency - Dormant Projects
  • Exocrine Pancreatic Insufficiency - Discontinued Products
  • Exocrine Pancreatic Insufficiency - Product Development Milestones
    • Featured News & Press Releases
      • May 15, 2017: Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura
      • Apr 11, 2017: AzurRx Provides Update on MS1819 Phase II Trial
      • Dec 21, 2016: AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency
      • Nov 17, 2016: AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients
      • Jun 28, 2016: Anthera Provides Clinical Program Update for Sollpura
      • Mar 19, 2015: Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura - a Novel Enzyme Therapy
      • Nov 20, 2014: Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
      • Aug 01, 2012: Cilian Receives €1m Grant For Development Of Cilase
      • Apr 15, 2011: Lilly Receives Complete Response Letter From FDA For Liprotamase For Treatment Of Exocrine Pancreatic Insufficiency
      • Jan 12, 2011: Lilly Announces FDA Panel Recommendation For Liprotamase
      • Jun 22, 2010: Protea Biosciences And Mayoly-­Spindler Announce Human Clinical Trial For New Biopharmaceutical.
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Exocrine Pancreatic Insufficiency, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals Inc, H1 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Celleron Therapeutics Ltd, H1 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H1 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler SAS, H1 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co KG, H1 2017
  • Exocrine Pancreatic Insufficiency - Dormant Projects, H1 2017
  • Exocrine Pancreatic Insufficiency - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Exocrine Pancreatic Insufficiency, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top